- Home
- TGTX vs PAGP Comparison
TGTX vs PAGP Comparison
Compare TGTX & PAGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TGTX | PAGP |
|---|---|---|
| Founded | 1993 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Natural Gas Distribution |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.0B |
| IPO Year | 1995 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TGTX | PAGP |
|---|---|---|
| Price | $27.70 | $21.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 7 |
| Target Price | ★ $50.67 | $20.17 |
| AVG Volume (30 Days) | ★ 2.4M | 2.1M |
| Earning Date | 03-02-2026 | 02-06-2026 |
| Dividend Yield | N/A | ★ 7.88% |
| EPS Growth | N/A | ★ 11.94 |
| EPS | ★ 2.78 | 0.95 |
| Revenue | $531,898,000.00 | ★ $46,917,000,000.00 |
| Revenue This Year | $89.24 | N/A |
| Revenue Next Year | $47.32 | $11.39 |
| P/E Ratio | ★ $10.00 | $22.41 |
| Revenue Growth | ★ 100.88 | N/A |
| 52 Week Low | $25.28 | $16.61 |
| 52 Week High | $46.48 | $21.97 |
Technical Indicators
Market Signals| Indicator | TGTX | PAGP |
|---|---|---|
| Relative Strength Index (RSI) | 34.42 | 72.71 |
| Support Level | $28.60 | $20.08 |
| Resistance Level | $32.55 | $21.23 |
| Average True Range (ATR) | 1.04 | 0.39 |
| MACD | -0.21 | 0.02 |
| Stochastic Oscillator | 0.10 | 94.37 |
Price Performance
Historical ComparisonAbout TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About PAGP Plains GP Holdings L.P. Units representing Limited Partner Interests
Plains GP Holdings LP provides transportation, storage, processing, fractionation, and marketing services for crude oil, refined products, natural gas liquids, liquefied petroleum gas, and related products. The group manages its operations through two operating segments: Crude Oil and NGL.